<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02503644</url>
  </required_header>
  <id_info>
    <org_study_id>IVA_01_337_HSSC_15_001</org_study_id>
    <nct_id>NCT02503644</nct_id>
  </id_info>
  <brief_title>Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis</brief_title>
  <acronym>FASST</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multicentre Proof-of-concept Trial of IVA337 in the Treatment of Diffuse Cutaneous Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inventiva Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inventiva Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systemic sclerosis (SSc), or scleroderma is a connective tissue disease of autoimmune origin.
      It is a life-threatening orphan disease with severe physical and psychosocial consequences.
      IVA337 has a novel mechanism of action and this study is designed to compare IVA337 at two
      dose levels with a placebo control treatment. Patients will be unaware of the treatment they
      are receiving and will be randomized to one of three treatment arms , either IVA337 400mg
      bid, IVA337 600mg bid or placebo bid. They will receive drug for 48 weeks and during that
      time assessments will be made to monitor both the efficacy and safety of the treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design: randomized, double-blind, placebo-controlled, multicentre phase 2
      proof-of-concept trial of IVA337 for the treatment DcSSc.

      The treatments are randomly assigned. The randomisation is stratified for background therapy
      to ensure even distribution of background therapies among treatment groups.

      There are 3 parallel treatment groups: placebo, IVA337 400mg bid and IVA337 600mg bid
      (identical capsules of 200mg IVA337 or placebo). Both, patient and investigator are blinded.

      The treatment lasts 48 weeks. A follow-up assessment takes place 12 weeks after the last
      dose.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of skin thickness by the Modified Rodnan Skin Score (MRSS)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Mean change of the MRSS from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rates based on MRSS improvement</measure>
    <time_frame>12, 24, 32, 48, and 60 weeks</time_frame>
    <description>MRSS response rates; improvers are defined by a reduction ≥5 points and ≥25 % of MRSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall progression of the disease: defined as absence of rescue therapy and absence of severe organ involvement</measure>
    <time_frame>28, 32,40, and 48 weeks</time_frame>
    <description>Overall progression of the disease: defined as absence of rescue therapy and absence of severe organ involvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function measured by FVC% predicted</measure>
    <time_frame>24 and 48 weeks</time_frame>
    <description>Change in pulmonary function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function by cDLCO% predicted</measure>
    <time_frame>24 and 48 weeks</time_frame>
    <description>Change in pulmonary function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scleroderma Health Assessment Questionnaire (SHAQ)</measure>
    <time_frame>24, 48, and 60 weeks</time_frame>
    <description>Changes in patient reported outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal tract symptoms severity and its impact on patients' well-being assessed by the UCLA SCTC GIT</measure>
    <time_frame>24, 48, and 60 weeks</time_frame>
    <description>Changes in patient reported outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported health status assessed by PROMIS29</measure>
    <time_frame>24, 48, and 60 weeks</time_frame>
    <description>Changes in patient reported outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical and mental health assessed by SF36</measure>
    <time_frame>24, 48, and 60 weeks</time_frame>
    <description>Changes in patient reported outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digital ulcer net burden (defined as total number of ulcers at a certain time point minus number of ulcers at baseline) and proportion of patients who do not develop new ulcers</measure>
    <time_frame>12, 24, 32, 48, and 60 weeks</time_frame>
    <description>Digital ulcer net burden (defined as total number of ulcers at a certain time point minus number of ulcers at baseline) and proportion of patients who do not develop new ulcers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hand function assessed by the Cochin Hand Function Scale</measure>
    <time_frame>12, 24, 32, 48, and 60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global assessment of disease activity assessed by a visual analogue scale</measure>
    <time_frame>24, 48, and 60 weeks</time_frame>
    <description>Patient global assessments of disease activity (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician global assessment of disease activity assessed by a visual analogue scale</measure>
    <time_frame>24, 48, and 60 weeks</time_frame>
    <description>Physician global assessment of disease activity (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Combined Response Index for Systemic Sclerosis (CRISS)</measure>
    <time_frame>24, 48, and 60 weeks</time_frame>
    <description>Composed of five variables: MRSS, FVC % predicted, physician and patient global assessments, and HAQ-DI score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patients who need escape therapy</measure>
    <time_frame>28, 32,40, and 48 weeks</time_frame>
    <description>Need for escape therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patients who experience a new severe organ involvement</measure>
    <time_frame>2, 4, 8,12, 16, 24, 28, 32, 40, 48, and 60 weeks</time_frame>
    <description>Severe organ involvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>2, 4, 8,12, 16, 24, 28, 32, 40, 48, and 60 weeks</time_frame>
    <description>Frequency and type of AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Routine and specific laboratory tests (composite) to assess safety and tolerability</measure>
    <time_frame>2, 12, 24, 32, 48, and 60 weeks</time_frame>
    <description>creatine kinase, N-terminal pro-brain natriuretic peptide, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, γ-glutamyl transferase, total bilirubin, direct bilirubin,RBC and WBC count, reticulocytes, haemoglobin, haematocrit, albumin , Quick, aPTT, INR, BUN, plasma creatinine, microalbuminuria, homocysteine, urinalysis (dip stick), glycated haemoglobin, creatine phosphokinase increase, platelet counts, plasma osteocalcin, serum beta C-terminal telopeptide (β-CTx or B-Crosslaps), Differential: neutrophils, eosinophils, basophils, monocytes, lymphocytes, cholesterol, triglycerides, albumin, total protein, C-reactive protein (CRP), adiponectin, serology HIV and hepatitis infection: Hep. A antibodies, B antibodies and antigen, C antibodies, serum b-HCG.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Raynaud attacks assessed by a diary and the Raynaud condition score (VAS)</measure>
    <time_frame>Daily during week 9 and week 25</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Progression of the disease assessed by changes of the activity of specific SSc biomarkers in the blood</measure>
    <time_frame>12, 24, and 48 weeks</time_frame>
    <description>Mean changes in activity biomarkers</description>
  </other_outcome>
  <other_outcome>
    <measure>Progression of the disease assessed by changes of the activity of specific SSc biomarkers in the skin</measure>
    <time_frame>48 weeks</time_frame>
    <description>Mean changes in activity biomarkers</description>
  </other_outcome>
  <other_outcome>
    <measure>Population pharmacokinetics to confirm the pharmacokinetic profile, including Cmax, Tmax, AUC, half-life (t1/2), clearance (CL/F) and volume of distribution (Vd/F)</measure>
    <time_frame>2, 24, and 48 weeks</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Scleroderma, Diffuse</condition>
  <condition>Diffuse Cutaneous Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>IVA337 800mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive twice daily 400mg IVA337.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IVA337 1200mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive twice daily 600mg IVA337.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive twice daily placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVA337</intervention_name>
    <description>Capsules of 200mg IVA337</description>
    <arm_group_label>IVA337 800mg</arm_group_label>
    <arm_group_label>IVA337 1200mg</arm_group_label>
    <other_name>No other names at present</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identical capsules without active substance</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>No other names at present</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed Consent documented by signature

          -  Systemic sclerosis according to ACR/EULAR 2103 criteria (van de Hoogen 2013)

          -  Diffuse cutaneous SSc subset according to LeRoy's criteria

          -  Diagnosis within the past 3 years as defined by the first non-Raynaud's symptom

          -  MRSS between 10 and 25

          -  Age between 18 and 75, male or female

        Patients on stable treatment (for &gt;3 months) with prednisone ≤ 10 mg, methotrexate≤ 20
        mg/w, azathioprine ≤ 150 mg/d, mycophenolate mofetil ≤ 2g/d, or leflunomide ≤ 20 mg/d may
        be included in the study; the therapy must be maintained as background therapy.

        Exclusion Criteria:

          -  Cyclophosphamide during the past 3 months

          -  Requirement of IV prostanoids for pulmonary hypertension in the last 3 months

          -  Renal insufficiency defined by a creatinine clearance of less than 30 ml/min (CKD-EPI
             or MDRD formula) and/or past/current renal crisis

          -  Hepatic impairment i.e. primary biliary cirrhosis and unexplained persistent liver
             function abnormality,

          -  Gallbladder disease (Cholelithiasis is not an exclusion criterion) Diabetic
             ketoacidosis

          -  Severe cardiac (LVEF &lt;45%) and/or pulmonary disease (FVC &lt; 50% or pulmonary
             hypertension proven by right heart catheterisation)

          -  History of heart failure, symptomatic coronary artery disease, significant ventricular
             tachyarrhythmia, stent placement, coronary artery bypass surgery, and/or myocardial
             infarction.

          -  Recipient of solid organ transplant

          -  Gastrointestinal involvement preventing oral administration of study drug

          -  Chronic infections, positive serology for infection with hepatitis B or C.

          -  Pregnancy, Lactation. Woman of childbearing potential unwilling to use a medically
             acceptable form of birth control

          -  History of malignancy within the last 5 years, except for resected basal or squamous
             cell carcinoma, treated cervical dysplasia, or treated in situ cervical cancer

          -  A recent history of alcohol or drug abuse, non-compliance with other medical therapies

          -  Participation in a clinical study involving another investigational drug or device
             within 4 weeks before the Pre-treatment Visit

          -  Laboratory parameters at the pre-treatment visit showing any of the following abnormal
             results: transaminases &gt; 2x the upper limit of normal (ULN) and/or bilirubin &gt; 2x ULN;
             neutrophil count &lt; 1,500/mm3; platelet count &lt; 100,000/mm3; haemoglobin &lt; 9 g/dL

          -  Contraindications to the class of drugs under study (PPAR agonists), e.g. known
             hypersensitivity or allergy to class of drugs or the investigational product

          -  Any condition or treatment, which in the opinion of the investigator, places the
             subject at unacceptable risk as a patient in the trial

        Co-therapy with biologics: Wash-out period: Any anti-TNF agent in the last 3-months:
        adalimumab, certolizumab, etanercept, golimumab, infliximab; abatacept in the last 3
        months; rituximab in the last 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yannick Allanore, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université Paris Descartes, Hôpital Cochin, Service de Rhumatologie A &amp; INSERM, Paris, France,</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher Denton, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Free Hospital NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille- Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Lapeyronie CHRU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff-Klinik</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité- Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaité-Universtätsmedezin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univertaetsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Erlangen-Nuremberg</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIRI GmbH Centrum für Innovative Diagnostik und Therapie</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik fur Dermatologie und Venerologie der Universitat zu Köln</name>
      <address>
        <city>Köln</city>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kilinik für Hautkrankenheiten</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universtätsklinik Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Clinica Medica Generale Polo Didattico</name>
      <address>
        <city>Ancona</city>
        <zip>60020</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedalaria Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Salvatore ASL L'Aquila</name>
      <address>
        <city>L'Aquila</city>
        <zip>67100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Federico II</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Alta Specializzazione &quot;San Camillo&quot;</name>
      <address>
        <city>Roma</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita degli Studi de Verona</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Miriada Prywatny</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital in Bydgoszcz</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CM Plejady</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumed</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medycine Centrum Hetmanska Poznan</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Oporow</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Universitario Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr Peset</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Lausanne</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Institut of Rheumatic and Musculoskeletal Medicine</name>
      <address>
        <city>Leeds</city>
        <zip>LS7 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2015</study_first_submitted>
  <study_first_submitted_qc>July 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2015</study_first_posted>
  <last_update_submitted>November 22, 2017</last_update_submitted>
  <last_update_submitted_qc>November 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diffuse cutaneous systemic sclerosis</keyword>
  <keyword>scleroderma</keyword>
  <keyword>IVA337</keyword>
  <keyword>dcSSc</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

